353519-63-8

HLM006474 is a non-selective inhibitor of the transcription factor E2F (IC₅₀ = 29.8 μM for E2F4). It inhibits DNA binding to E2F1, E2F2, and E2F4 in A375 melanoma cells when used at a concentration of 40 μM. HLM006474 (40 μM) decreases protein levels of E2F4 and cyclin D3 and induces apoptosis in A375 cells. It also induces apoptosis in MDA-MB-231, but not MCF-7, cells and inhibits the growth of cancer cells in a panel of 17 lung cancer cell lines (IC₅₀s = 15.5-75.1 μM). HLM006474 reduces tumor growth in retinoblastoma-prone Chx10Cre;Rb^fl/fl;p107^-/- mice and in an A375 mouse xenograft model when administered at a dose of 100 mg/kg and 2 mg per mouse, respectively.

HLM 006474 acts as an E2F transcription factor inhibitor, preventing DNA binding activity. This results in the induction of apoptosis in breast cancer cells.

HLM006474 has been used as an E2 factor?(E2F) inhibitor in human nasopharyngeal carcinoma hone-1 cells and T. annulata-infected TBL20 cells.

A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC₅₀ = 30 μM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).

HLM006474 is a pan-E2F transcription factor inhibitor. E2F s part of the CDK/Rb/E2F pathway. When phosphorylated by CDKs, the tumor suppressor retinoblastoma protein (Rb) is inactivated, releasing E2Fs and allowing cell cycle progression. HLM006474 inhibited DNA-binding of all E2F complexes and down-regulated expression of E2F4 protein. HLM006474 induced apoptosis of A375 melanoma cells and synergized with paclitaxel in lung cancer cell lines.